everolimus + imatinib

A combination therapy of **everolimus**, a mammalian target of rapamycin (mTOR) inhibitor, and **imatinib**, a tyrosine kinase inhibitor that targets KIT, ABL, and PDGFR-A/B kinases. This combination has been investigated primarily for advanced renal cell carcinoma and gastrointestinal stromal tumors (GIST) resistant to imatinib. Everolimus inhibits mTORC1-mediated cell growth and proliferation, while imatinib blocks receptor tyrosine kinases including PDGFR, potentially reducing cell survival and angiogenesis[1][3][5]. The rationale for the combination is dual blockade of mTOR-driven proliferation and PDGFR-mediated angiogenesis and tumor progression. While some studies confirm pharmacokinetic interaction (imatinib increases everolimus exposure), clinical efficacy has not shown clear improvement over either agent alone in tested indications[1][3][5].

Brand names

GleevecAfinitor

Other names

everolimus + imatinibeverolimus plus imatinib mesylate